Vulvovaginal pyoderma gangrenosum associated with rituximab use in 2 patients with rheumatoid arthritis

摘要

Patient 1: Pre- and post-treatment. A, Suppurative vulvovaginal pyoderma gangrenosum prior to removal of rituximab. B, Vulvovaginal pyoderma gangrenosum 3 months after removal of rituximab and following 2 cycles of 2 g/kg IVIg. IVIg, Intravenous immunoglobulin.